Navigation Links
FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation
Date:2/23/2017

TORONTO, Feb. 23, 2017 /PRNewswire/ - The Fight Against Cancer Innovation Trust (FACIT) and the Ontario Institute for Cancer Research (OICR) are pleased to report that Fusion Pharmaceuticals Inc. (Fusion) has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as the lead investor. Additional, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT. 

Fusion's therapeutic approach leverages alpha particle-emitting technology combined with monoclonal antibodies to target cancer cells with great precision, reducing damage to normal tissues and thereby limiting side effects. Alpha-particle emitting medical isotopes attack cancer cells using multiple mechanisms, including causing the type of DNA damage that the cancer cell cannot easily repair, reducing the likelihood of developing drug resistance. At the same time, alpha particle-emitting agents offer improved safe-handling features and can be administered in conventional cancer treatment facilities unlike previous generations of radiotherapeutics.

Fusion is a spin-out company from the Centre for Probe Development and Commercialization (CPDC), which received OICR funding support from its inception and has grown to be a global leader in the clinical development and manufacturing of radioimaging and radiotherapeutic products. As OICR's commercialization partner, FACIT provided corporate leadership (through its Executive-in-Residence program) as well as seed funding to launch Fusion and to attract the strategic partners, investors and the larger capital infusion necessary to grow the company, and continue its research around radiotherapeutics. 

"Fusion's platform is rooted in CPDC's expertise in radiolabelling technologies and provides new opportunities to impact patients with next generation radiotherapeutics," said Peter Goodhand, Interim President of the OICR. "Thanks to the translational research funding support that OICR receives from the Ontario Ministry of Research, Innovation and Science, we are able to support initiatives like CPDC; it's a terrific success story." 

"FACIT's initial investment in Fusion has created significant leverage with this Series A financing, and has also resulted in a stronger and deeper therapeutic pipeline, along with high-value, skilled jobs," said Jeff Courtney, President of FACIT. "The Province will also benefit from the presence of investors like JJDC, HealthCap and TPG Biotech that possess deep commercialization networks and specialized expertise in building successful companies. This financing showcases how public and private sector cooperation can create the innovations that benefit patients worldwide and importantly, Ontario's knowledge economy. "

Proceeds from the Series A financing will support and accelerate the clinical development of Fusion's lead program FPX-01, which targets a specific resistance biomarker present on many types of refractory cancers. The financing will also enable Fusion to build its product pipeline through development of its newly acquired centryin-based targeting technology platform, which is in preclinical development.

About the Fight Against Cancer Innovation Trust (FACIT)             
Established by the Ontario Institute for Cancer Research (OICR) as a strategic partner to accelerate commercialization of oncology innovations, the Fight Against Cancer Innovation Trust (FACIT) helps bring these innovations from the lab to the marketplace to benefit patients, researchers, investors and the Ontario economy. For more information, please visit the website at facit.ca or email info@facit.ca

About the Ontario Institute for Cancer Research
OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, supported by the Government of Ontario. OICR's research supports more than 1,700 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing. For more information, please visit the website at www.oicr.on.ca.

About Fusion Pharmaceuticals, Inc.
Fusion Pharmaceuticals is a new pharmaceutical company located in Hamilton, Ontario, Canada focused on becoming the leader in the targeted alpha therapy field. Fusion will exploit its unique expertise in linking medical isotopes to targeting molecules to create highly effective therapeutics. In addition to its lead program, FPX-01, Fusion is building a pipeline of products through a protein discovery platform that allows for the rapid screening of new targeting molecules to promote biomarker localization of alpha emitting medical isotopes. Fusion's technology development team also has proprietary methods for introducing alpha emitters into targeting molecules. (www.fusionpharma.com)


'/>"/>
SOURCE Fight Against Cancer Innovation Trust
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. NDIS Approval of Promega PowerPlex® Fusion System Assists Laboratories in Meeting Evolving Standards
2. Surefire Medical Launches Next Generation Infusion System ST-LT and Specialty Catheters at SIR - Maximizing Targeted Delivery of Embolics Without Reflux
3. GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit
4. ConfometRx Awarded Patent on GPCRs that Contain a Stabilizing IC2 Fusion Protein
5. Emergent and DiFusion Form Strategic Partnership to Take CleanFuze™ Antimicrobial Implants to Market
6. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
7. Surefire Medicals Anti-Reflux Infusion System May Eliminate Coiling, Lower Cost Of Embolization Procedures
8. Rudolf Kingslake Medal Awarded by SPIE for TNO Paper on Color Image Fusion for Night-Vision Applications
9. Case Report Published in the Journal Perfusion on 14-Year-Old Pediatric Patient Bridged to Transplant with SynCardia Total Artificial Heart
10. Engineered T-Cell Receptor in Fusion Proteins, Antibodies & Cells Industry Trend: Worldwide Industry Latest Market Share, Investment Trends, Growth, Size, Strategy
11. Science Group Says Article on DNA Barcode Analysis of Herbs Is Flawed, Contains Errors, Creates Confusion, and Should Be Retracted
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... announced today that they have been selected by Lantern Pharma to provided preclinical ... designed to obtain millions of data points using panels of unique and genetically ...
(Date:11/9/2019)... ... November 08, 2019 , ... ... intelligence (AI)-powered technology for use in pathology research, today announced the results ... samples from patients enrolled in the phase 3 selonsertib studies (STELLAR). Strong ...
(Date:11/5/2019)... , ... November 05, 2019 , ... Ole, a German Shepherd, was demonstrating signs of ... and jumping. Though his energy level and his willingness to play were normal, it ... Dr. Holly Mullen of VCA Emergency Animal Hospital and Referral Center in San ...
(Date:10/30/2019)... ... October 30, 2019 , ... Western ... many roles innovation and technology play in educating the next generation of health ... learning opportunities and presentations by WesternU administrators and representatives of companies working with ...
Breaking Biology Technology:
(Date:11/6/2019)... ... 06, 2019 , ... Genomenon® announced the ... includes the ability to search the entirety of the genomic literature by phenotypes ... rare diseases. , Patients, particularly those with rare diseases, don’t always have a ...
(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current ... device industries. Access to all webinars is free, so be sure to register today ... , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , ...
(Date:10/30/2019)... ... October 30, 2019 , ... ... from several venture capital firms, including Fenbushi Capital, DF Capital, Rising Tide Fund, ... and experience enabling Amberdata to further accelerate its position as the leading data ...
Breaking Biology News(10 mins):